ADC Therapeutics SA (ADCT)
| Market Cap | 147.81M |
| Revenue (ttm) | 122.57M |
| Net Income (ttm) | -178.51M |
| Shares Out | 89.04M |
| EPS (ttm) | -2.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 457,832 |
| Open | 1.59 |
| Previous Close | 1.59 |
| Day's Range | 1.52 - 1.70 |
| 52-Week Range | 0.36 - 5.75 |
| Beta | 1.24 |
| Analysts | Hold |
| Price Target | 4.20 (+153.01%) |
| Earnings Date | Feb 27, 2024 |
About ADCT
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a mon... [Read more]
Financial Performance
In 2022, ADCT's revenue was $209.91 million, an increase of 518.89% compared to the previous year's $33.92 million. Losses were -$155.80 million, -32.27% less than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ADCT stock is "Hold." The 12-month stock price forecast is $4.2, which is an increase of 153.01% from the latest price.
News
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads bas...
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that th...
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
3Q 2023 ZYNLONTA® 1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferi...
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m....
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibo...
ADC Therapeutics to Participate in September Investor Conferences
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in S...
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
2Q 2023 ZYNLONTA® 1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. E...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK , July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contac...
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: AD...
ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy
ADC Therapeutics said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for treating a type of blood cancer over safety concern...
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial (Cli...
ADC Therapeutics Announces Evolution of Board of Directors
Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE, Switzerland, Ju...
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in...
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferi...
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in ...
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Glob...
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the first quarter 2023 and provided an updated corporate strategy. “2023 is a pivotal year...
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financi...
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securi...
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43rd Annual Health Car...